Druggable CSNK2A1-MeCP2 regulatory axis links Okur-Chung neurodevelopmental syndrome with MECP2-related disorders
The brain is exquisitely sensitive to methyl-CpG-binding protein 2 (MeCP2) abundance. Too little causes Rett syndrome (RTT), too much causes MECP2 duplication syndrome (MDS), and in both, severity tracks with the amount of functional MeCP2. Even modest deviations are detrimental, yet how MeCP2 abundance is controlled remains poorly understood. Using genome-wide CRISPR knockout screens, we…
The brain's delicate balance of MeCP2 levels is tightly regulated. When MeCP2 is too scarce, Rett syndrome emerges; when overly abundant, MECP2 duplication syndrome results. In both cases, the severity hinges on MeCP2's functionality. Even minor fluctuations in MeCP2 abundance are detrimental. However, the mechanism controlling MeCP2 levels remains largely unknown.
Utilizing genome-wide CRISPR knockout screens, researchers pinpointed hundreds of proteins involved in MeCP2 regulation, revealing a casein kinase 2 alpha 1 (CSNK2A1)-driven regulatory axis that stabilizes MeCP2. This axis is deemed druggable and holds therapeutic potential. By employing a novel CSNK2A1 inhibitor in human cells and targeting Csnk2a1 in an MDS mouse model, the researchers demonstrated the therapeutic relevance of this axis.
Furthermore, they established a connection between CSNK2A1-MeCP2 regulatory disruption and Okur-Chung neurodevelopmental syndrome (OCNDS), a condition caused by mutations in CSNK2A1. Their findings indicate that OCNDS mice exhibit approximately 50% reduced hippocampal MeCP2 levels. In summary, these results identify a druggable regulatory axis that modulates MeCP2 and suggest that MeCP2 dysregulation plays a role in the molecular pathogenesis of OCNDS and potentially other neurodevelopmental disorders.
Written by urgent.news from bioRxiv's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
